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SUMMARY 
• HIV-1, the etiological agent of AIDS, enters cells 
within minutes after binding to a receptor molecule, fusing 
its membrane with the cell membrane and uncoating its enve- 
lope to deliver the RNA-protein complex into the cell cyto- 
plasm. The infection cycle then proceeds for hours to days 
through a series of steps, including reverse transcription of 
the viral RNA, integration of the resulting DNA into the cel- 
lular genome, transcription of the proviral DNA, expression 
of vims proteins, their assembly and virus budding, leading 
to production of progeny virions. Virus spread by subsequent 
cycles of infection occurs within weeks and months, while 
AIDS develops after years or even decades. This review dis- 
cusses the causes of this diversity in kinetics, emphasizing the 
importance of quantitation, and how quantitation of infec- 
tion kinetics may help in understanding the factors that affect 
the disease progression. 
INTRODUCTION 
• HIV-1, the etiological agent of AIDS (2,21,30), 
enters cells by binding to a receptor molecule, CD4 (11,29), 
fusing its membrane with the cell membrane (43) and 
uncoating its envelope to deliver the RNA-protein com- 
plex into cell cytoplasm (24). The infection cycle then proc- 
ceeds through a series of steps, including reverse tran- 
scription of the viral RNA, integration of the resulting 
DNA into the cellular genome, transcription of the provi- 
ral DNA, expression of virus proteins, their assembly and 
virus budding, leading to production of progeny virions 
(45). While the HIV entry takes minutes and hours, pro- 
ductive infection of cells requires days to complete. Virus 
spread by subsequent cycles of infection occurs within 
weeks and months, while AIDS develops after years or 
even decades. Understanding the causes of this diversity 
in time scales is critical for understanding the factors that 
affect the disease progression. Here I present a current 
view on virus entry, infection and AIDS progression, 
emphasizing the quantitation of their kinetics. 
HIV-1 ENTRY INTO CELLS 
• HIV-1 envelope glycoprotein binding to receptor 
molecules  
Human immunodeficiency virus (HIV-1) enters cells by 
utilizing a high affinity interaction between the viral gly- 
coprotein (gp!20-gp41 complex) and the cellular recep- 
tor CD4 (11,29). There are few studies on binding of intact 
virions to cells and studies on binding of infected to target 
cells are lacking. In contrast, there a number of studies 
with soluble recombinant gp 120 and CD4 (35). It was 
found that sCD4 binds with high affinity to gp 120 and 
inhibits viral infection and syncytia formation in vitro 
(9,12,20,26,42,44). The high affinity of the CD4-gpl20 
interaction and the presumption that the soluble receptor 
molecule efficiently interact with a wide variety (theoreti- 
cally with all) of viral isolates led to human clinical trials 
(27,41). The trials showed that sCD4 did not change the 
patient status and cooled the enthusiasm about sCD4. To 
find out possible reasons for the failure of the clinical tri- 
als and to better understand the nature of the CD4-gpl20 
binding we studied thoroughly the binding of sCD4 to 
membrane-associated gp!20-gp41. 
We measured the rate constants of sCD4 binding and dis- 
sociation (16,17) and found that in contrast to previous 
work of others (36) the affinity of binding is not affected 
by temperature (16). Interestingly*, the rate of binding of 
  
  
sCD4 and inhibition of HIV-1 infection at concentrations 
used in human clinical trials (about 0.1 Mg/ml) was slow 
while the dissociation was fast (17,18). We suggested that 
this property of the gp!20-gp41-sCD4 interaction is one of 
the causes for the failure of sCD4 as an anti-HIV-1 agent 
in those trials (17,18).  
• HIV-1 envelope glycoprotein-mediated mem- 
brane fusion 
The binding of the membrane-associated HIV-1 envelope 
glycoprotein to its membrane receptor CD4, initiates a 
complex cascade of phenomena, which ultimately result in 
fusion of the viral membrane with the plasma membrane 
of the cell and virus entry (3,35,43). Cells which express 
the viral proteins also fuse with CD4 target cells, which in 
some cases is dramatically manifested by formation of 
giant cells (syncytia) (31,32). While the expression of the 
gp!20-gp41 is sufficient to induce fusion after interaction 
with membrane-associated CD4, a number of factors 
determine the rate and efficiency of the fusion process. It 
was found, for example, that many animal cells express- 
ing human CD4 do not fuse with gp!20-gp41 expressing 
cells (1,5,33). Mutations in and antibodies against the V3 
loop of gp!20, which is the principal neutralizing domain 
of the envelope glycoprotein and does not overlap the CD4 
binding site, can abrogate the fusion activity, without 
affecting binding (reviewed in [35]). It was suggested that 
the CDR3 in the first domain of CD4 also plays a role in 
post-binding events (reviewed in [40]), but recent exten- 
sive mutational studies (4) questioned this hypothesis. 
Other domains of CD4, however, are certainly important 
in post-binding events as demonstrated by mAbs directed 
to the second (7,10) and third (25) domains of CD4 and 
chimeric CD4-CD8 molecules (38). 
In most of the studies on fusion syncytia formation has 
been used as an indicator of cell fusion and lack of syncy- 
tia has been assumed as a proof for lack of fusion. In other 
studies fusion was measured at one point in time and lack 
of syncytia at that time point was assumed to indicate lack 
of fusion. To avoid limitations of other assays we devel- 
oped a method for measuring membrane fusion based on 
fluorescence dye redistribution and videomicroscopy, and 
extensively studied the kinetics of fusion for a number of 
systems.  
We attempted to identify the kinetic and molecular com- 
ponents of the overall fusion process (3). We measured 
the rate of fusion of cells expressing gp!20-gp41 (15) and 
found that while the lag times in cell fusion are in the range 
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fusion are much shorter (1-2 min) (18). The fusion rate 
was critically dependent on the level of expression of 
gp!20-gp41 (13) and the membrane proximal domains of 
CD4 (23). There was a correlation between the rate of 
membrane fusion and formation of giant cells (syncytia) 
(17). We also found that calcium ions are required for effi- 
cient fusion (14) and an additional component(s) ofhuman 
cells confers the ability of animal cells expressing human 
CD4 to fuse (5). Interestingly, fusion of human B cell lines 
with gp!20-gp41 expressing cells was enhanced by anti- 
gen-specific immunoglobulin receptors, which may indi- 
cate existence of a mechanism for specific depletion in vivo 
of B cells expressing anti-gp!20-gp41 antibodies (22). The 
knowledge gained in studying binding and fision mediat- 
ed by the CD4-gpl20-gp41 allowed us to develop a novel 
approach to inhibit HIV-1 infection and syncytia forma- 
tion which is based on CD4-plasma membrane vesicles 
(39) and may prove useful in the therapy of AIDS. 
• Uncoating of the virus envelope         
Fusion of the viral membrane with the cell membrane is 
followed by uncoating of the virus envelope and penetra- 
tion of the virus core through an opening of 20 to 80 nm 
in size (24). It seems that core disintegrates and releases 
the viral nucleoprotein complex through this opening 
because morphologically intact virus cores were not seen 
in the cytoplasm beneath the fusion zone. The release of 
the virus genome into the cell cytoplasm occurs within 3- 
10 min at 37°C (24). The mechanisms of envelope uncoat- 
ing are presently unclear and the exact time sequence of 
events unknown. One may speculate that the virus enve- 
lope uncoating is similar to the initial stages of syncytia 
formation following fusion of the cell membranes. 
However, what is the role of the interaction of the virus 
core with the envelope during its uncoating remains to be 
elucidated. 
REPLICATION OF THE VIRAL GENOME AND 
VIRUS ASSEMBLY 
• The replication of the HIV-1 genome can be divid- 
ed into two main stages: the first phase is carried our prin- 
cipally by enzymes found in the virus and includes reverse 
transcription of the viral RNA and integration of the result- 
ing DNA into the cellular genome; the second phase, which 
includes synthesis of progeny genomes and mRNAs, and 
their translation, is carried out by cellular enzymes. 
Processing of the virus proteins involves both virus and cel- 
lular enzymes, while assembly of progeny virions, includ- 
ing budding, occurs spontaneously and does not seem to 
require enzymatic activity. It appears that efficient repli- 
cation of the viral genome requires integration of the virus 
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DNA in the cellular genome, which can be the limiting fac- 
tor in the kinetics of virus replication. 
• Synthesis of viral DNA and its integration into 
the cellular genome  
The synthesis of viral DNA is carried out by the concert- 
ed action of a virus-specific RNA-dependent DNA poly- 
merase and a virus-specified ribonuclease H (37), and 
occurs in the cytoplasm of the cell immediately after the 
uncoating of the viral envelope within the first 6 h of infec- 
tion (28). The overall process of reverse transcription leads 
from a molecule of single-stranded RNA with the struc- 
ture R-U5-genes-U3-R (R,U5 and U3 being a repeated 
sequence, and unique sequences, respectively, which are 
involved in the reverse transcription, and transcription ini- 
tiation and regulation) to a molecule of double-stranded 
linear DNA of the structure U3-R-U5-genes-U3-R-U5. 
The sequence U3-R-U5 thus constitutes a long terminal 
repeat (LTR) which serves as an HIV-1 promoter. 
The linear DNA molecules associated with matrix proteins 
and other virus components are transported to the nucle- 
us of the host cell in a process which is independent of cell 
division but requires ATP: features which are indicative of 
an active transport process (6). Circular DNA molecules 
are detectable in the nucleus 8 to 12 h after the virus entry 
and increase in number during the next 20 h (28). The next 
event is the integration of the viral DNA into that of the 
host. The integration is mediated by a virus-associated 
enzyme, the integrase, which has three functions: it trims 
the ends of the duplex DNA; it cleaves the host DNA; and 
finally it covalently joins the freshly cut ends of the virus 
and host DNA (8). This reaction occurs in the cell nucle- 
us, where nuclear enzymes repair the site of insertion. Once 
integrated, viral DNA (provirus) remains permanently 
associated with the cellular genome. It is replicated regu- 
larly along with the cell DNA and loss of provirus (if occurs) 
seems to be a consequence of random deletion events, 
rather than a result of provirus instability. 
• Expression of viral genes and their regulation 
Expression of virus components begins with the synthesis 
of a complete RNA copy of the proviral DNA. The rate 
of transcription is controlled by cellular proteins. A large 
family of proteins binds to sequences near the site of RNA 
initiation of transcription and either increase or decrease 
the rate of initiation or/and elongation. For example, provi- 
ral DNA is not transcribed in resting T cells. As most of 
the CD4 positive cells in the circulation are resting, little 
virus is made by this population of cells. However, specif- 
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results in active RNA transcription. The ability of the virus 
to remain silent in the cell account in part for the long 
latent period of the HIV-1 disease. 
After activation of the HIV-1 provirus by cellular factors, 
the first viral genes to be expressed are those which encode 
nonstructural proteins with regulatory functions (45). The 
most important of the viral factors is the Tat protein which 
is needed for efficient transcription of the viral RNA. Tat 
is thought to act by two possible mechanisms: by helping 
to initiate the RNA transcription or/and by ensuring the 
production of full-length RNA transcripts during the RNA 
elongation step. The Tat protein is a powerful transacti- 
vator and inscreases tremendously the number of infec- 
tions virions produced by infected cells, which leads to 
rapid spread of the virus. 
The full-length RNA transcripts are then multiply spliced 
and transported to the cytoplasm where the HIV-1 regu- 
latory proteins are expressed. At this stage another regu- 
latory protein, Rev, which affects the transport of unspliced 
and singly spliced mRNA from the nucleus to the cyto- 
plasm, becomes essential. These unspliced and singly 
spliced mRNAs encode the structural and enzymatic pro- 
teins of HIV-1 which are needed for assembly of virions. 
The temporal aspects of RNA synthesis show a complex 
pattern (28). HIV-1 specific RNA appears first at 12 to 16 
h postinfection and increases thereafter. There are early 
and late transcriptional phases. Early mRNAs are pre- 
dominantly the smaller one: presumably the 2-kb spliced 
mRNAs for the low-molecular weight regulatory proteins 
(tat, rev) and the 4.3-kb spliced mRNAs which represents 
predominantly env, and possibly others. However, full-size 
transcripts (9.2 kb), which act both as the genome for the 
virus and as the mRNA for the gag and pol genes, were 
also evident in albeit small amounts. The late phase cor- 
relates with the appearance of Rev. After 24 h only 9.2-kb 
mRNA is made. The significant delay in the full-level 
expression of the full (9.2 kb), and to a lesser extent, the 
4.3 kb mRNA species is somewhat similar to the asymp- 
totic stage in the progression of the HIV-1 disease. A 
hypothesis (28) suggests that a controlled shift from the 
early to the late transcriptional phases may represent the 
transition from the latent to the acute infection in vivo. 
• Virus assembly and release 
The assembly and release of virions by budding is an unusu-; 
al process in at least two aspects. First, assembly and bud- 
ding occur simultaneously. Second, analysis of mutants 
shows that only a relatively small fraction of the virion pro- 




RNA still yield normal-appearing virions, except for the 
absence of surface knobs. Thus capsid formation and bud- 
ding are determined by only core and matrix proteins. The 
capsid precursor protein and the capsid replicative enzyme 
precursor proteins coassemble at the inner surface of the 
cell membrane. These proteins insert themselves into the 
cell membrane by virtue of a myristic acid which is attached 
to the amino terminus of the capsid precursor protein. The 
complex of capsid protein, replicative enzyme precursor, 
, and viral RNA assemble into a closed spherical particle 
which buds through the cell membrane. The newly assem- 
bled particle appears to remain attached by a tether to the 
surface of the cell before release. What is the time dura- 
tion of the virus assembly and release is unknown but it 
appears to be relatively rapid and ptobably occurs within 
minutes provided appropriate conditions as, e.g. high con- 
centration of virus components. 
HIV-1 SPREADING KINETICS IN VITRO Km AIDS 
PROGRESSION 
• The first description of the acquired immune defi- 
ciency syndrome (AIDS) appeared in 1981, and described 
26 patients with Kaposi' s sarcoma and 5 - with oral thrush 
and pheumocystis pneumonia. The connection between 
the two groups was that the patients were all young male 
homosexual and their diseases were usually associated with 
iatrogenic immunosuppression. It was soon recognized 
that the epidemiology or distribution of cases is charac- 
teristic of a blood associated virus transmission via blood 
contact, via sexual intercourse and perinatally. Initially the 
definition of AIDS required the clinical diagnosis of con- 
ditions that were moderately predictive of cellular immun- 
odeficiency, without an underlying cause, but later this def- 
inition was revised to include serological evidence of HIV 
infection. In an attempt to ease the problem of definition, 
the Centers for Disease Control (CDC) in Atlanta devel- 
oped a classification system, which details four mutually 
 
exclusive categories of HIV-1 infection as shown in Table 
1. This classification system is shown to demonstrate the 
complexity of the HIV-1 infection in vivo, but is not meant 
to suggest that every individual has to progress through all 
stages. However, patients having reached a particular stage 
do not revert to earlier stages if the symptoms settle. 
• HIV-1 infection kinetics in tissue cultures 
According to CDC classification system there are three 
major stages in the kinetics of HIV-1 infection leading to 
AIDS: (i) acute infection, (ii) asymptomatic phase, and 
(iii) AIDS-related complex and AIDS. The acute infection 
stage is characterized by an initial short period (days to 
weeks) without detectable virus; the viral load then sharply 
increases reaching a peak after several weeks and then 
slowly decreases in parallel with an increase in the con- 
centration of antibodies against the virus components. As 
AIDS progresses the antibody titer decreases and the 
viremia increases. Interestingly, the infection of permis- 
sive T cells by HIV-1 in tissue cultures resembles some of 
the features of the acute infection in vivo and the late stages 
of AIDS. It typically proceeds in three stages: (i) no 
detectable virus production, (ii) a sharp increase in virus 
concentration reaching a peak, and (iii) a decline in virus 
production. The lag times without detectable virus pro- 
duction and the time periods to reach the peak of virus 
infection are critically dependent on the number of infec- 
tious virions produced by an infected cell and the time 
needed for the virus replication. While the replication times 
can be estimated by infecting cells with high multiplicities 
of infection (MOIs), measurement of the number of infec- 
tious virions during the virus transmission is more com- 
plicated if not impossible with the current assays, because 
of the cell-to-cell spread of the virus and its rapid inacti- 
vation. 
To gain insight into the kinetic mechanisms of HIV-1 infec- 
tion and to quantitate the critical parameters of a spread- 
ing infection, we developed a new approach, based on a 
combination of empirical data and theoretical modeling 
(19). We measured the kinetics of cell aggregation, cyto- 
pathicity and virus production at different MOI and 
described it by empirical equations. Then we derived those 
equations by using a model of virus spread by subsequent 
cycles of infection, which allowed us to calculate the time 
required for one cycle of infection and the number of infec- 
tious virions produced by one infected cell during this cycle. 
Interestingly, we found that the number of infectious viri- 
ons is much higher (10 ^ to ICP-fold) under conditions 
which favor cell fusion than the HIV-1 infectivity in cul- 
ture supernatants. Another important conclusion from our 
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analysis is that the slow infection kinetics of an HIV-1 tat 
minus mutant is not due to a longer replication time but 
reflects the low number (approximately 10) of infectious 
particles produced per cycle. While the infective process 
in vivo is much more complex than in tissue cultures (34), 
the evaluation of the critical parameters of a spreading 
infection by acutely infected cells may provide a basis for 
further insight into the mechanisms of AIDS progression. 
• Acute infection in patients 
Primary infection with HIV-1 may be associated with acute 
clinical manifestations, for example, sore throat, non-spe- 
cific flu-like symptoms and gastrointestinal disturbances. 
The incubation period, defined as the time from exposure 
to clinical symptoms of acute infection, is variable, rang- 
ing from a few days to up to a few months. It is felt that 
the incubation period may be longer in sexually transmit- 
ted infection possibly because of a smaller dose of inocu- 
lum (see above for a discussion of an in vitro analogue) 
and the non-parenteral route of transmission. However, 
incubation periods of up to 6 months have been docu- 
mented via the parenteral route. Symptoms of the illness 
last in average 1-2 weeks and up to 3-4 weeks and are 
accompanied by viremia. Specific antibodies can be detect- 
ed (seroconversion) from 8 days to 10 weeks after the onset 
of acute illness. Antibodies to gp!20, gp!60 and p24 devel- 
op first and antibodies to gp41 and other viral antigens 
develop about 4 weeks later. 
Severe immunodepression may occur during acute HIV-1 
infection. This is probably related to the selective loss of 
antigen-primed T-memory cells, as well as defects which 
are present in the B cells and monocyte compartments. 
The number of CDS cells increases, while the number of 
CD4 cells decreases in parallel with the increase in viral 
load. This pattern is preserved following recovery from the 
acute infection. The return to normality in the CDS and 
CD4 cells is incomplete. 
• Asymptotic phase 
The asymptotic phase of HIV-1 infection may last for many 
years. The CD4 cell number declines almost linearly with 
time during the early stages of the disease at an average 
rate of 60-100 cells/mm  ̂per year. The slope of CD4 decline 
varies within individual patient population and seems to 
be related to the biological properties of individual viral 
isolates. Syncytia-inducing isolates were associated with 
steep decline and early development of symptomatic dis- 
ease, while slowly replicating non-syncytia-forming strains 
were associated with low rates of short-term progression. 







tissue cultures, this can be attributed to the different num- 
ber of infectious particles produced by the two types of 
viral strains. 
• AIDS-related complex and AIDS 
With the loss of CD4 cells the symptoms of opportunistic 
infections rise steadily. Some studies have reported that 
the CD4 trend may enter a phase of accelerated and rapid 
decline immediately prior to the development of AIDS, 
although other cohorts have failed to confirm this trend 
and report a linear falls throughout the natural history. The 
rate of CD4 decline is variable between individuals, and 
the level at which an AIDS-defining infection or tumor 
occurs is also variable. There is an approximate hierarchy 
of opportunistic infections present at different stages of 
the accumulating immunodeficiency. For example, herpes 
zoster occurs on average 5 years prior to development of 
AIDS. Oral Candida occurs later and is associated with 
CD4 numbers below 300/mm^. The most frequent oppor- 
tunistic infection, Pneumocystis pneumonia, is common 




The viral load increases with the progression of AIDS both 
as cell-free virus and provirus. The viremia in the blood 
serum can reach 1(P or more infectious units per ml, and 
the number of CD4 cells containing provirus compared to 
uninfected CD4 cells is in the range of 1:10 to 1:100. The 
titer of the antibodies, especially against structural pro- 
teins, e.g.p24, decreases, but antibodies against the enve- 
lope glycoproteins are still present in relatively high con- 
centrations. Under those conditions the virus probably 
spreads by cell fusion. How exactly the interplay between 
the immune system and virus behavior leads to the steady 
loss of the CD4 cells, disease and death remains to be elu- 
cidated. Quantitation of the time course of HIV-1 infec- 
tion and its interpretation based on studies in vitro and the- 
oretical modeling is one of the major approaches which 
can provide such knowledge needed for understanding the 
mechanisms leading to AIDS progression. 
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